Paul Brinkman
Overview
Explore the profile of Paul Brinkman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
81
Citations
1025
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
van Poelgeest J, Shahbazi Khamas S, Hallawa A, DAlessandro C, DAlessandro C, Ferreira R, et al.
J Breath Res
. 2025 Feb;
19(2).
PMID: 39999477
Chronic obstructive pulmonary disease (COPD) exacerbations significantly contribute to disease progression, hospitalizations, and decreased quality of life. Early detection of exacerbations through non-invasive methods, such as exhaled volatile organic compounds...
2.
Alizadeh Bahmani A, Vijverberg S, Hashimoto S, Wolff C, Almqvist C, Bloemsma L, et al.
ERJ Open Res
. 2024 Dec;
10(6).
PMID: 39687398
Background: Underlying immunological mechanisms in children with moderate-to-severe asthma are complex and unclear. We aimed to investigate the association between blood inflammatory parameters and asthma burden in children with moderate-to-severe...
3.
Kermani N, Chung K, Macis G, Santini G, Clemeno F, Versi A, et al.
Eur Respir J
. 2024 Oct;
64(5).
PMID: 39401856
Background: Lung quantitative computed tomography (qCT) severe asthma clusters have been reported, but their replication and underlying disease mechanisms are unknown. We identified and replicated qCT clusters of severe asthma...
4.
Chudy S, Phanzu D, Kolk A, Sopoh G, Barogui Y, Tzfadia O, et al.
PLoS Negl Trop Dis
. 2024 Sep;
18(9):e0012514.
PMID: 39312571
Diagnosing Buruli ulcer (BU) is complicated by limited access to the sensitive IS2404 qPCR. Experienced clinicians report a distinct odour of Buruli ulcers. We explored the potential of headspace analysis...
5.
Nessen E, Toussaint B, Israels J, Brinkman P, der Zee A, Haarman E
J Clin Med
. 2024 Jun;
13(12).
PMID: 38929901
Disorders of mucociliary clearance, such as cystic fibrosis (CF), primary ciliary dyskinesia (PCD) and bronchiectasis of unknown origin, are characterised by periods with increased respiratory symptoms, referred to as pulmonary...
6.
Brinkman P, Wilde M, Ahmed W, Wang R, van der Schee M, Abuhelal S, et al.
Am J Respir Crit Care Med
. 2024 Jun;
210(9):1079-1090.
PMID: 38889337
The exhaled breath represents an ideal matrix for noninvasive biomarker discovery, and exhaled metabolomics have the potential to be clinically useful in the era of precision medicine. In this concise...
7.
Peltrini R, Cordell R, Wilde M, Abuhelal S, Quek E, Zounemat-Kermani N, et al.
Am J Respir Crit Care Med
. 2024 May;
210(9):1101-1112.
PMID: 38820123
Volatile organic compounds (VOCs) in asthmatic breath may be associated with sputum eosinophilia. We developed a volatile biomarker signature to predict sputum eosinophilia in asthma. VOCs emitted into the space...
8.
de Jong F, Lilien T, Fenn D, Wingelaar T, van Ooij P, Maitland-van der Zee A, et al.
Metabolites
. 2024 May;
14(5).
PMID: 38786758
Volatile organic compounds (VOCs) might be associated with pulmonary oxygen toxicity (POT). This pilot study aims to identify VOCs linked to oxidative stress employing an in vitro model of alveolar...
9.
Shahbazi Khamas S, Van Dijk Y, I Abdel-Aziz M, Neerincx A, Maarten Blankestijn J, Vijverberg S, et al.
Am J Respir Crit Care Med
. 2024 Apr;
210(9):1091-1100.
PMID: 38648186
The early identification of children with poorly controlled asthma is imperative for optimizing treatment strategies. The analysis of exhaled volatile organic compounds (VOCs) is an emerging approach to identify prognostic...
10.
Djukanovic R, Brinkman P, Kolmert J, Gomez C, Schofield J, Brandsma J, et al.
Am J Respir Crit Care Med
. 2024 Apr;
210(3):288-297.
PMID: 38635834
The anti-IgE monoclonal antibody omalizumab is widely used for severe asthma. This study aimed to identify biomarkers that predict clinical improvement during 1 year of omalizumab treatment. One-year open-label Study...